Want to see LGVN full AI Analyst Report?
LGVN Stock Chart & Stats
$0.60
>-$0.01(-1.19%)
At close: 4:00 PM EDT
$0.60
>-$0.01(-1.19%)
Day’s Range― - ―
52-Week Range$0.48 - $1.23
Previous CloseN/A
Volume160.25K
Average Volume (3M)473.11K
Market Cap
$26.94M
Enterprise Value$12.56
Total Cash (Recent Filing)$10.08M
Total Debt (Recent Filing)$581.00K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding30,432,974
10 Day Avg. Volume706,553
30 Day Avg. Volume473,105
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$1.54M
Bulls Say, Bears Say
Bulls Say
IP And Regulatory PositionA broad patent estate and multiple expedited FDA designations can protect the platform, support differentiated regulatory pathways, and improve partnering potential if clinical results validate laromestrocel.
Multi-Indication Cell Therapy PlatformDeveloping one allogeneic MSC platform across several high-need indications diversifies clinical opportunities and allows research, manufacturing, and regulatory capabilities to be leveraged across programs.
Low Financial LeverageMinimal debt reduces interest and creditor pressure while clinical programs advance. Although equity has been volatile, low leverage gives the company more flexibility than a highly indebted biotech during future financing or partnering efforts.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that development activities require substantial external funding. Continued cash consumption may constrain trial execution and force financing or partnering before programs mature.
Minimal Revenue And Large LossesLimited and declining revenue provides little internal funding, while rising expenses and widening losses indicate no near-term operating leverage. The company remains dependent on clinical success before meaningful commercial economics can emerge.
Clinical And Funding DependencyThe investment case depends heavily on the upcoming Phase 2b readout and subsequent regulatory interactions. With a limited runway, unfavorable data or delays could reduce partnering options and increase dilution or execution risk.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.47 and its highest was $1.23 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $26.94M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Nov 06, 2026 which is in 75 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on Aug 12, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.175 by -$0.015.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -0.16.
How many shares outstanding does Longeveron have?
Longeveron has 30,432,974 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.175. Following the earnings report the stock price went down -6.568%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Longeveron
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
LGVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific, regulatory, and validation milestones (upcoming ELPIS II readout, XPRIZE finalist award, high-profile publications, strong IP and expedited designations, and regulatory progress for PDCM) against material financial constraints (very low revenues, rising expenses, widening net loss, and a cash runway into Q4 2026). The business outlook is highly dependent on the imminent trial readout and the company's ability to secure partnerships or financing to extend the runway and commercialize programs.View all LGVN earnings summariesLGVN Stock 12 Month Forecast
Average Price Target
$3.00
▲(400.00% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
19.14% Insiders
2.17% Mutual Funds
5.08% Other Institutional Investors
71.70% Public Companies and
Individual Investors